Flecainide: Current status and perspectives in arrhythmia management

Table 1 Reversion rate of recent-onset atrial fibrillation to sinus rhythm in clinical trials evaluating the conversion efficacy of oral or intravenous flecainide

Clinical trial	Patients in flecainide arm	AF duration	Formulation	Reversion rate
Capucci et al[38]	22 patients	≤ 7 d	Single oral dose (300 mg)	8 h → 91%
				24 h → 95%
Donovan et al[39]	51 patients	≤ 3 d	iv (2 mg/kg-max 150 mg)	1 h → 57%
				6 h → 67%
Donovan et al[40]	34 patients	≤ 3 d	iv (2 mg/kg-max 150 mg)	2 h → 59%
				8 h → 68%
Boriani et al[41]	69 patients	< 8 d	Single oral dose (300 mg)	1 h → 13%
				3 h → 57%
				8 h → 75%
Martínez-Marcos et al[42]	50 patients	≤ 2 d	iv (2 mg/kg followed by 1 mg/kg at 8 h if not SR)	1 h → 58%
				8 h → 82%
				12 h → 90%
Romano et al[43]	138 patients	≤ 3 d	Intravenous	1 h → 73%
				3 h → 80%
				6 h → 86%
				24 h → 90%

AF: Atrial fibrillation; SR: Sinus rhythm.